This method uses an easier and not invasive peripheral blood sample in respect with the FISH assay (PathVysion FISH assay) performed on tumor biopsies actually approved by the US Food and Drug Administration (FDA) for determining the eligibility for Herceptin clinical treatment in breast carcinoma with erbB2 amplification. The gene discussed is ERBB2; the disease is breast carcinoma.